ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
A randomized double-blind, placebo controlled clinical trial of the safety, tolerability, and
antiviral activity of angiotensin-converting enzyme 2 (ACE2) chewing gum over a 3-day period
in non-hospitalized subjects with Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) infection.